The U.S. Food and Drug Administration (FDA) is continuing to review data from published studies to evaluate whether the use of oral bisphosphonates is associated with an increased risk of esophageal ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Due to its marked efficacy in the prevention of bone loss in susceptible populations, alendronate (generic name of BIS) had been proposed as a useful agent to prevent alveolar bone loss. [22] One ...

NEW YORK (Reuters Health) Jan. 3 A report in the Journal of the American Dental Association for January clarifies the risk of jaw osteonecrosis associated with bisphosphonates. Intravenous ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving long-term glucocorticoids should use oral bisphosphonates to reduce the risk for bone loss ...

Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study ...

STUDY QUESTION Test of a prior hypothesis: does use of oral bisphosphonates increase the risk of oesophageal cancer? SUMMARY ANSWER In a large UK primary care cohort, having 10 or more prescriptions ...

The association between oral bisphosphonate (BP) intake and colorectal cancer (CRC) risk has been investigated in several recent studies with conflicting results. We summarized the evidence from the ...

Philadelphia, PA - A review of jaw osteonecrosis as a recently described adverse effect of bisphosphonate therapy in the May 16, 2006 issue of the Annals of Internal Medicine concludes that most cases ...

(Corrects to show Actonel is owned by Warner Chilcott, 4th paragraph) * FDA says no thigh fracture risk with bisphosphonates * Bisphosphonates such as Fosamax treat osteoporosis * FDA statement ...

ByMiller PD, Pannacciulli N, Brown JP, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016, 101(8) ...

LONDON--(BUSINESS WIRE)--FOR MEDICAL BUSINESS/INDUSTRY TRADE MEDIA ONLY A real world evidence study, presented at the 13 th International Conference on Osteoporosis, Arthritis and Musculoskeletal ...